Alpha M Beta 2 integrin blockade for acute inflammatory neuropathies

Alpha M Beta 2 整合素阻断治疗急性炎症性神经病

基本信息

  • 批准号:
    8281893
  • 负责人:
  • 金额:
    $ 23.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our objective is to evaluate whether inhibition of alpha M beta2integrin-dependent leukocyte infiltration into peripheral nerves is a specific therapy for acute peripheral nerve inflammation seen in immune-mediated disorders and neuropathic pain. Using acute inflammatory demyelinating polyradiculoneuropathy (AIDP; the most common variant of Guillain-Barr¿ syndrome [GBS]) as an example of acute severe peripheral nerve inflammation, we propose to address a fundamental question: Is blockade of ¿M integrin (CD11b) a potential treatment strategy for acute peripheral neuritis? Based on our exciting new preliminary data using in vitro and in vivo approaches, we propose the following hypothesis: ¿M¿2 integrin expressed on activated hematogenous monocytes and lymphocytes and ICAM-1 expressed on activated endoneurial endothelial cells interact and recruit pathogenic mononuclear leukocytes across the blood-nerve barrier in AIDP. As an extension of this, we propose that competitive inhibition with an ¿M integrin monoclonal antibody would reduce pathogenic leukocyte trafficking at the blood-nerve barrier. Reduction in leukocyte infiltration ino peripheral nerves would limit the harmful consequences of severe peripheral nerve inflammation, demyelination and axonal injury in GBS. This strategy provides an opportunity to develop a novel targeted therapy for AIDP and neuropathic pain. In order to address this hypothesis, we will determine that a function neutralizing monoclonal antibody against human ¿M integrin reduces trafficking of untreated AIDP patient peripheral blood mononuclear leukocytes on a novel cytokine-stimulated human in vitro blood-nerve barrier model that incorporates capillary flow rates. Trafficking events would be captured in real-time and quantified by video microscopy. We will also evaluate the effect of ¿M integrin blockade on the behavioral, electrophysiological and histopathological features of acute peripheral nerve inflammation, demyelination and axonal injury in a severe, reliable GBS mouse model, using our published methods. Current therapies for GBS and other peripheral nerve inflammatory disorders, as well neuropathic pain are non-specific and partly effective. This proposal is a preclinical evaluation of ¿M integrin antagonism as a targeted anti-inflammatory therapy for AIDP. Inhibiting disease-specific inflammatory pathways has the potential to revolutionize the treatment of acute, severe peripheral nerve inflammation. The proposed work could lead towards the development of novel monoclonal antibody therapies for phase I clinical trials in AIDP and other inflammatory neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy (an under-recognized neuropathy that may account for 14% of disabling neuropathies in patients over 65 years of age), as well as neuropathic pain.
描述(由申请人提供):我们的目的是评估抑制α M β 2整合素依赖的白细胞浸润周围神经是否是免疫介导疾病和神经性疼痛中出现的急性周围神经炎症的特异性治疗。以急性炎症性脱髓鞘性多根神经病变(AIDP,吉兰-巴尔综合征[GBS]的最常见变体)为例,我们提出解决一个基本问题:阻断M整合素(CD11b)是急性周围神经炎的潜在治疗策略吗?基于我们使用体外和体内方法的令人兴奋的新初步数据,我们提出以下假设:活化的造血单核细胞和淋巴细胞上表达的¿M¿2整合素和活化的神经内皮细胞上表达的ICAM-1相互作用,并在AIDP中通过血神经屏障招募致病性单核白细胞。作为这一研究的延伸,我们提出用一种¿M整合素单克隆抗体进行竞争性抑制可以减少血神经屏障处的致病性白细胞运输。减少外周神经中白细胞的浸润将限制GBS严重外周神经炎症、脱髓鞘和轴索损伤的有害后果。这一策略为开发AIDP和神经性疼痛的新型靶向治疗提供了机会。为了解决这一假设,我们将确定一种针对人¿M整合素的功能中和单克隆抗体,在一种新的细胞因子刺激的人体外血液-神经屏障模型上,结合毛细血管流速,可以减少未经治疗的AIDP患者外周血单核白细胞的运输。贩运事件将通过视频显微镜实时捕获和量化。我们还将使用我们已发表的方法,在严重、可靠的GBS小鼠模型中评估¿M整合素阻断剂对急性周围神经炎症、脱髓鞘和轴索损伤的行为、电生理和组织病理学特征的影响。目前治疗GBS和其他周围神经炎症性疾病以及神经性疼痛的方法是非特异性的,部分有效。该建议是对整合素拮抗剂作为AIDP靶向抗炎治疗的临床前评估。抑制疾病特异性炎症通路有可能彻底改变急性,严重周围神经炎症的治疗。拟议的工作可能会导致开发新的单克隆抗体治疗AIDP和其他炎性神经病变的I期临床试验,如慢性炎性脱髓鞘性多根神经病变(一种未被认识的神经病变,可能占65岁以上患者致残神经病的14%),以及神经性疼痛。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eroboghene Ekamereno Ubogu其他文献

Eroboghene Ekamereno Ubogu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eroboghene Ekamereno Ubogu', 18)}}的其他基金

Alpha-1 catenin regulation of the mammalian blood-nerve barrier
Alpha-1 连环蛋白对哺乳动物血神经屏障的调节
  • 批准号:
    9978422
  • 财政年份:
    2020
  • 资助金额:
    $ 23.48万
  • 项目类别:
Vascular biology of the human blood-nerve barrier
人类血神经屏障的血管生物学
  • 批准号:
    8811628
  • 财政年份:
    2012
  • 资助金额:
    $ 23.48万
  • 项目类别:
Alpha M Beta 2 integrin blockade for acute inflammatory neuropathies
Alpha M Beta 2 整合素阻断治疗急性炎症性神经病
  • 批准号:
    8812344
  • 财政年份:
    2012
  • 资助金额:
    $ 23.48万
  • 项目类别:
Alpha M Beta 2 integrin blockade for acute inflammatory neuropathies
Alpha M Beta 2 整合素阻断治疗急性炎症性神经病
  • 批准号:
    8436191
  • 财政年份:
    2012
  • 资助金额:
    $ 23.48万
  • 项目类别:
Vascular biology of the human blood-nerve barrier
人类血神经屏障的血管生物学
  • 批准号:
    8649094
  • 财政年份:
    2012
  • 资助金额:
    $ 23.48万
  • 项目类别:
Vascular biology of the human blood-nerve barrier
人类血神经屏障的血管生物学
  • 批准号:
    8294254
  • 财政年份:
    2012
  • 资助金额:
    $ 23.48万
  • 项目类别:
Vascular biology of the human blood-nerve barrier
人类血神经屏障的血管生物学
  • 批准号:
    8843554
  • 财政年份:
    2012
  • 资助金额:
    $ 23.48万
  • 项目类别:
Fibronectin peptide antagonism for chronic inflammatory neuropathies
纤连蛋白肽拮抗慢性炎症性神经病
  • 批准号:
    8338443
  • 财政年份:
    2011
  • 资助金额:
    $ 23.48万
  • 项目类别:
Fibronectin peptide antagonism for chronic inflammatory neuropathies
纤连蛋白肽拮抗慢性炎症性神经病
  • 批准号:
    8240721
  • 财政年份:
    2011
  • 资助金额:
    $ 23.48万
  • 项目类别:
Fibronectin peptide antagonism for chronic inflammatory neuropathies
纤连蛋白肽拮抗慢性炎症性神经病
  • 批准号:
    8739889
  • 财政年份:
    2011
  • 资助金额:
    $ 23.48万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了